Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVEREST II: Ranibizumab and Verteporfin PDT in Symptomatic Macular PCV
NCT01846273Phase 4Completed
- Sponsor
- Novartis
- Start
- Aug 2013
- Primary completion
- Mar 2016
- Countries
- 7
01
Overview
A Phase 4 trial of verteporfin in polypoidal choroidal vasculopathy (PCV), sponsored by Novartis. Started Aug 2013; status: completed.
02
Drugs
verteporfin
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on NCT01846273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01846273.